Author

Karin Malíčková 1

1 Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty and General Teaching H

BIOSIMILAR INFLIXIMAB IS EFFECTIVE AND SAFE IN INFLAMMATORY BOWEL DISEASE PATIENTS NAIVE TO ANTI-TNF THERAPY: A TERTIARY CENTER EXPERIENCE

Martin Bortlík, Martin Kolar, Dana Duricova, Karin Malíčková, Veronica Hruba, Nadezda Machkova, Katarina Mitrova, Martin Lukas, Milan Lukas

EFFICACY OF INFLIXIMAB BIOSIMILAR CT-P13 INDUCTION THERAPY ON MUCOSAL HEALING IN ULCERATIVE COLITIS

Tamás Molnár, Renáta Bor, Mariann Rutka, Petra Anna Golovics, Zsuzsanna Vegh, Barbara Dorottya Lovasz, Tibor Nyári, Krisztina Barbara Gecse, Martin Kolar, Martin Bortlík, Dana Duricova, Nadezda Machkova, Veronica Hruba, Martin Lukas, Katarina Mitrova, Karin Malíčková, Anita Balint, Ferenc Nagy, Renáta Bor, Ágnes Milassin

FREQUENCY AND CHARACTERISTICS OF INFUSION REACTIONS DURING BIOSIMILAR INFLIXIMAB TREATMENT IN INFLAMMATORY BOWEL DISEASES: RESULTS FROM CENTRAL EUROPEAN NATIONWIDE COHORT

Anita Balint, Mariann Rutka, Zsuzsanna Vegh, Zsuzsanna Kürti, Krisztina Barbara Gecse, János Banai, László Bene, Beata Gasztonyi, Tünde Kristóf, László Lakatos, Pal Miheller, Karoly Palatka, Árpád V. Patai, Ágnes Szabone Salamon, Tamás Szamosi, Zoltan Gabor Szepes, Gábor Tamás Tóth, Aron Vincze, Renáta Bor, Ágnes Milassi

Impact of the switch from original adalimumab to biosimilar adalimumab SB5 on serum drug trough levels, clinical and biological disease activity in patients with IBD

Milan Lukas, Veronika Pešinová, Martin Bortlík, Dana Duricova, Nadezda Machkova, Veronika Hruba, Martin Lukas, Martin Vašátko, Karin Malíčková

INFLIXIMAB BIOSIMILAR CT-P13 THERAPY IS EFFECTIVE IN MAINTAINING ENDOSCOPIC REMISSION IN ULCERATIVE COLITIS – RESULTS FROM MULTICENTRE OBSERVATIONAL COHORT

Klaudia Farkas, Anita Balint, Mariann Rutka, Martin Kolar, Martin Bortlík, Dana Duricova, Veronika Hruba, Martin Lukas, Katarina Mitrova, Karin Malíčková, Milan Lukas, Zoltan Gabor Szepes, Ferenc Nagy, Karoly Palatka, Szilvia Lovas, Zsuzsanna Vegh, Zsuzsanna Kürti, Agnes Anna Csontos, Pal Miheller, Renáta Bor, Ágnes Mil

NO DIFFERENCE IN IMMUNOGENICITY OF THE ORIGINAL AND BIOSIMILAR INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Karin Malíčková, Dana Duricova, Martin Kolar, Martin Bortlík, Veronica Hruba, Nadezda Machkova, Katarina Mitrova, Martin Lukas, Milan Lukas

POINT-OF-CARE TESTING SYSTEM FOR FECAL CALPROTECTIN DETECTION IN THE TELEMONITORING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Karin Malíčková

Point-of-care testing system for fecal calprotectin detection in the telemonitoring of patients with inflammatory bowel diseases

Karin Malíčková, Veronika Pešinová, Martin Bortlík, Dana Duricova, Nadezda Machkova, Veronika Hruba, Martin Lukas, Martin Vašátko, Milan Lukas

SERUM TROUGH SB5 LEVELS: A COMPARISON OF TWO DIFFERENT IMMUNOASSAYS FOR THE MONITORING OF BIOSIMILAR ADALIMUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Karin Malíčková

Serum trough SB5 levels: A comparison of two different immunoassays for the monitoring of biosimilar adalimumab treatment in patients with inflammatory bowel disease

Karin Malíčková, Martin Bortlík, Dana Duricova, Nadezda Machkova, Veronika Hruba, Martin Lukas, Martin Vašátko, Katarina Mitrova, Marta Kostrejova, Milan Lukas

Item 1 - 10 / 15
1
2